Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial.
Lobo, et al, The Lancet, Volume 385, No. 9978 April 25, 2015
The authors discuss the results of the RH-02 clinical trial. They assessed the safety and efficacy of a central iliac arteriovenous anastomosis to alter the mechanical arterial properties and reduce blood pressure in patients with uncontrolled hypertension.
The ROX coupler: Creation of a fixed iliac arteriovenous anastomosis for the treatment of uncontrolled systemic arterial hypertension, exploiting the physical properties of the arterial vasculature
Foran, et al, Catheterization Cardiovascular Interventions Volume 85, Issue 5 April 2015
The authors describe the technical aspects of the ROX coupler device and implantation procedure, results from a preclinical study, patient selection criteria, and potential complications of this therapy for uncontrolled hypertension.
Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension
Faul et al, JVS, April 2014, Volume 59, Issue 4, pages 1078-1083
The authors discuss the findings of a twenty-four patient open label study of arteriovenous shunt creation in patients with COPD and hypertension. The authors conclude that a percutaneous iliac arteriovenous fistula creation for COPD causes a significant and persistent lowering of blood pressure for those with co-existing hypertension.
The Thrill of success: central arterial-venous anastomosis for hypertension, Current Hypertension Reports, 2014 December; 16(12):1522-6417 (Print) 1534-3111 (Online)
Marat Fudim, Alice Stanton, Paul A Sobotka, Eamon Dolan, and Henry Krum, Current Hypertension Reports, December 2014, 16:497
The authors examine the potential of a fixed-volume central arterial-venous anastomosis to reduce blood pressure in hypertensive patients, review possible mechanisms by which the anastomosis may reduce blood pressure, and consider the unique clinical trial opportunities posed by this therapy.
Venous Admixture in COPD: Pathophysiology and Therapeutic Approaches, COPD, 2008 December; 5(6): 376–381.
Christopher B. Cooper, Bartolome Celli.
The authors discuss in this perspective article the mechanism whereby venous admixture contributes to hypoxemia and reduced oxygen delivery to tissues. They explore methods which could potentially increase mixed venous oxygen content thus ameliorating the deleterious effects of venous admixture. The authors believe this approach to treatment could have significant impact for patients with COPD but should also benefit any patient with chronic hypoxemia that impairs exercise performance.